Yung-Sung Yeh Meng-Lin Huang Se-Fen Chang Chin-Fan Chen Huang-Ming Hu Jaw-Yuan Wang
10.1159/000358799
Med Princ Pract
2014;23(5):478-81.
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/24642571/
Adenocarcinoma / drug therapy Angiogenesis Inhibitors / administration & dosage Antibodies, Monoclonal, Humanized / administration & dosage Antineoplastic Combined Chemotherapy Protocols / therapeutic use Camptothecin / analogs & derivatives Colorectal Neoplasms / drug therapy Hyperbilirubinemia / complications
Adenocarcinoma / drug therapy Angiogenesis Inhibitors / administration & dosage Antibodies, Monoclonal, Humanized / administration & dosage Antineoplastic Combined Chemotherapy Protocols / therapeutic use Camptothecin / analogs & derivatives Colorectal Neoplasms / drug therapy Hyperbilirubinemia / complications Case Reports Research Support, Non-U.S. Gov't Adenocarcinoma / genetics Adenocarcinoma / secondary Bevacizumab Camptothecin / therapeutic use Colorectal Neoplasms / genetics Colorectal Neoplasms / pathology Fluorouracil / therapeutic use Genotype Glucuronosyltransferase / genetics Humans Hyperbilirubinemia / genetics Leucovorin / therapeutic use Liver Neoplasms / drug therapy Liver Neoplasms / genetics Liver Neoplasms / secondary Male Middle Aged Angiogenesis Inhibitors Antibodies, Monoclonal, Humanized Bevacizumab UGT1A1 enzyme Glucuronosyltransferase Leucovorin Fluorouracil Camptothecin IFL protocol
PMC5586907
24642571
FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping
2014